ArticleEuropean journal of medical research2026
Unveiling sex-specific cardiometabolic and adiposity risk profiles for precision prevention.
Article in European journal of medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCardiometabolic diseases (CMDs) are the leading global cause of mortality, driven by interrelated metabolic and cardiovascular factors. Sex differences significantly shape risk. We investigated sex-specific differences in cardiometabolic risk factors through univariate analyses and multivariate principal component analysis (PCA), with the goal of identifying meaningful patterns and potential biomarkers to support tailored prevention strategies.
methodsA cross-sectional study was conducted on 1715 individuals (929F/786 M; 58.1 ± 13.5 years). Clinical and biochemical variables were compared by sex, including markers of metabolic, atherogenic cardiovascular, and renal risk. All parameters were measured using certified and standardized methods to ensure reproducibility. PCA was applied to explore underlying patterns of association.
resultsCorrelation analyses revealed significant associations only between insulin resistance markers and atherogenic cardiovascular risk indices, suggesting largely independent effects of other parameters. In contrast, PCA identified coherent clusters: lipid/atherogenic markers, glycemic and insulin-resistance indices, and adiposity measures, while renal function emerged as a distinct domain. Sex differences were evident, with men displaying a less favorable cardiometabolic profile. PCA showed that in females, variance was mainly explained by triglyceride-related indices (TG, TG/HDL, AIP), adiposity measures, and blood pressure, whereas in males, lipid and atherogenic markers (TC, LDL, CRI indices, non-HDL, LCI) predominated, with adiposity and blood pressure forming separate clusters in both sexes. Lifestyle variables (smoking, alcohol consumption, fatigue) also modulated risk, whereas family history of diabetes and hypertension showed weak associations.
conclusionOverall, cardiometabolic risk emerges as a multidimensional construct shaped by distinct yet overlapping biological and behavioral domains, with sex and lifestyle exerting specific influences, underscoring the need for individualized, sex-specific prevention strategies. CLINICAL TRIAL: The study protocol was registered in ClinicalTrials.gov (ID: NCT0642756).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.